Global Opioid-Induced Constipation Market Insights and Forecast to 2028

Report ID: 1542646 | Published Date: Mar 2026 | No. of Page: 114 | Base Year: 2025 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Impact of U.S Tarrifs Analyzed 2025 

1 Study Coverage
    1.1 Opioid-Induced Constipation Product Introduction
    1.2 Market by Type
        1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Methylnaltrexone Bromide
        1.2.3 Lubiprostone
        1.2.4 Naloxegol
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Pharmacy
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Opioid-Induced Constipation Sales Estimates and Forecasts 2017-2028
    2.2 Global Opioid-Induced Constipation Revenue Estimates and Forecasts 2017-2028
    2.3 Global Opioid-Induced Constipation Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Opioid-Induced Constipation Sales by Region
        2.4.1 Global Opioid-Induced Constipation Sales by Region (2017-2022)
        2.4.2 Global Sales Opioid-Induced Constipation by Region (2023-2028)
    2.5 Global Opioid-Induced Constipation Revenue by Region
        2.5.1 Global Opioid-Induced Constipation Revenue by Region (2017-2022)
        2.5.2 Global Opioid-Induced Constipation Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Opioid-Induced Constipation Sales by Manufacturers
        3.1.1 Global Top Opioid-Induced Constipation Manufacturers by Sales (2017-2022)
        3.1.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Opioid-Induced Constipation in 2021
    3.2 Global Opioid-Induced Constipation Revenue by Manufacturers
        3.2.1 Global Opioid-Induced Constipation Revenue by Manufacturers (2017-2022)
        3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Opioid-Induced Constipation Revenue in 2021
    3.3 Global Opioid-Induced Constipation Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Opioid-Induced Constipation Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Opioid-Induced Constipation Sales by Type
        4.1.1 Global Opioid-Induced Constipation Historical Sales by Type (2017-2022)
        4.1.2 Global Opioid-Induced Constipation Forecasted Sales by Type (2023-2028)
        4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    4.2 Global Opioid-Induced Constipation Revenue by Type
        4.2.1 Global Opioid-Induced Constipation Historical Revenue by Type (2017-2022)
        4.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    4.3 Global Opioid-Induced Constipation Price by Type
        4.3.1 Global Opioid-Induced Constipation Price by Type (2017-2022)
        4.3.2 Global Opioid-Induced Constipation Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Opioid-Induced Constipation Sales by Application
        5.1.1 Global Opioid-Induced Constipation Historical Sales by Application (2017-2022)
        5.1.2 Global Opioid-Induced Constipation Forecasted Sales by Application (2023-2028)
        5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    5.2 Global Opioid-Induced Constipation Revenue by Application
        5.2.1 Global Opioid-Induced Constipation Historical Revenue by Application (2017-2022)
        5.2.2 Global Opioid-Induced Constipation Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    5.3 Global Opioid-Induced Constipation Price by Application
        5.3.1 Global Opioid-Induced Constipation Price by Application (2017-2022)
        5.3.2 Global Opioid-Induced Constipation Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Opioid-Induced Constipation Market Size by Type
        6.1.1 North America Opioid-Induced Constipation Sales by Type (2017-2028)
        6.1.2 North America Opioid-Induced Constipation Revenue by Type (2017-2028)
    6.2 North America Opioid-Induced Constipation Market Size by Application
        6.2.1 North America Opioid-Induced Constipation Sales by Application (2017-2028)
        6.2.2 North America Opioid-Induced Constipation Revenue by Application (2017-2028)
    6.3 North America Opioid-Induced Constipation Market Size by Country
        6.3.1 North America Opioid-Induced Constipation Sales by Country (2017-2028)
        6.3.2 North America Opioid-Induced Constipation Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Opioid-Induced Constipation Market Size by Type
        7.1.1 Europe Opioid-Induced Constipation Sales by Type (2017-2028)
        7.1.2 Europe Opioid-Induced Constipation Revenue by Type (2017-2028)
    7.2 Europe Opioid-Induced Constipation Market Size by Application
        7.2.1 Europe Opioid-Induced Constipation Sales by Application (2017-2028)
        7.2.2 Europe Opioid-Induced Constipation Revenue by Application (2017-2028)
    7.3 Europe Opioid-Induced Constipation Market Size by Country
        7.3.1 Europe Opioid-Induced Constipation Sales by Country (2017-2028)
        7.3.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Opioid-Induced Constipation Market Size by Type
        8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Type (2017-2028)
        8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Type (2017-2028)
    8.2 Asia Pacific Opioid-Induced Constipation Market Size by Application
        8.2.1 Asia Pacific Opioid-Induced Constipation Sales by Application (2017-2028)
        8.2.2 Asia Pacific Opioid-Induced Constipation Revenue by Application (2017-2028)
    8.3 Asia Pacific Opioid-Induced Constipation Market Size by Region
        8.3.1 Asia Pacific Opioid-Induced Constipation Sales by Region (2017-2028)
        8.3.2 Asia Pacific Opioid-Induced Constipation Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Opioid-Induced Constipation Market Size by Type
        9.1.1 Latin America Opioid-Induced Constipation Sales by Type (2017-2028)
        9.1.2 Latin America Opioid-Induced Constipation Revenue by Type (2017-2028)
    9.2 Latin America Opioid-Induced Constipation Market Size by Application
        9.2.1 Latin America Opioid-Induced Constipation Sales by Application (2017-2028)
        9.2.2 Latin America Opioid-Induced Constipation Revenue by Application (2017-2028)
    9.3 Latin America Opioid-Induced Constipation Market Size by Country
        9.3.1 Latin America Opioid-Induced Constipation Sales by Country (2017-2028)
        9.3.2 Latin America Opioid-Induced Constipation Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Opioid-Induced Constipation Market Size by Type
        10.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Type (2017-2028)
    10.2 Middle East and Africa Opioid-Induced Constipation Market Size by Application
        10.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Application (2017-2028)
    10.3 Middle East and Africa Opioid-Induced Constipation Market Size by Country
        10.3.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Takeda Pharmaceuticals
        11.1.1 Takeda Pharmaceuticals Corporation Information
        11.1.2 Takeda Pharmaceuticals Overview
        11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Takeda Pharmaceuticals Recent Developments
    11.2 Bayer
        11.2.1 Bayer Corporation Information
        11.2.2 Bayer Overview
        11.2.3 Bayer Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Bayer Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Bayer Recent Developments
    11.3 Sanofi
        11.3.1 Sanofi Corporation Information
        11.3.2 Sanofi Overview
        11.3.3 Sanofi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Sanofi Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Sanofi Recent Developments
    11.4 Mallinckrodt
        11.4.1 Mallinckrodt Corporation Information
        11.4.2 Mallinckrodt Overview
        11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Mallinckrodt Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Mallinckrodt Recent Developments
    11.5 Salix (Bausch Health)
        11.5.1 Salix (Bausch Health) Corporation Information
        11.5.2 Salix (Bausch Health) Overview
        11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Salix (Bausch Health) Recent Developments
    11.6 AstraZeneca
        11.6.1 AstraZeneca Corporation Information
        11.6.2 AstraZeneca Overview
        11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 AstraZeneca Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 AstraZeneca Recent Developments
    11.7 Progenics Pharmaceuticals
        11.7.1 Progenics Pharmaceuticals Corporation Information
        11.7.2 Progenics Pharmaceuticals Overview
        11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Progenics Pharmaceuticals Recent Developments
    11.8 Purdue Pharm
        11.8.1 Purdue Pharm Corporation Information
        11.8.2 Purdue Pharm Overview
        11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Purdue Pharm Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Purdue Pharm Recent Developments
    11.9 Nektar Therapeutics
        11.9.1 Nektar Therapeutics Corporation Information
        11.9.2 Nektar Therapeutics Overview
        11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Nektar Therapeutics Recent Developments
    11.10 Daiichi Sankyo
        11.10.1 Daiichi Sankyo Corporation Information
        11.10.2 Daiichi Sankyo Overview
        11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Daiichi Sankyo Recent Developments
    11.11 Prestige
        11.11.1 Prestige Corporation Information
        11.11.2 Prestige Overview
        11.11.3 Prestige Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Prestige Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Prestige Recent Developments
    11.12 GSK
        11.12.1 GSK Corporation Information
        11.12.2 GSK Overview
        11.12.3 GSK Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 GSK Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 GSK Recent Developments
    11.13 Shionogi
        11.13.1 Shionogi Corporation Information
        11.13.2 Shionogi Overview
        11.13.3 Shionogi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 Shionogi Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 Shionogi Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Opioid-Induced Constipation Industry Chain Analysis
    12.2 Opioid-Induced Constipation Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Opioid-Induced Constipation Production Mode & Process
    12.4 Opioid-Induced Constipation Sales and Marketing
        12.4.1 Opioid-Induced Constipation Sales Channels
        12.4.2 Opioid-Induced Constipation Distributors
    12.5 Opioid-Induced Constipation Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Opioid-Induced Constipation Industry Trends
    13.2 Opioid-Induced Constipation Market Drivers
    13.3 Opioid-Induced Constipation Market Challenges
    13.4 Opioid-Induced Constipation Market Restraints
14 Key Findings in The Global Opioid-Induced Constipation Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Methylnaltrexone Bromide
    Table 3. Major Manufacturers of Lubiprostone
    Table 4. Major Manufacturers of Naloxegol
    Table 5. Major Manufacturers of Others
    Table 6. Global Opioid-Induced Constipation Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Opioid-Induced Constipation Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
    Table 9. Global Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
    Table 10. Global Opioid-Induced Constipation Sales by Region (2023-2028) & (K Units)
    Table 11. Global Opioid-Induced Constipation Sales Market Share by Region (2023-2028)
    Table 12. Global Opioid-Induced Constipation Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Opioid-Induced Constipation Revenue Market Share by Region (2017-2022)
    Table 14. Global Opioid-Induced Constipation Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Opioid-Induced Constipation Revenue Market Share by Region (2023-2028)
    Table 16. Global Opioid-Induced Constipation Sales by Manufacturers (2017-2022) & (K Units)
    Table 17. Global Opioid-Induced Constipation Sales Share by Manufacturers (2017-2022)
    Table 18. Global Opioid-Induced Constipation Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2017-2022)
    Table 20. Opioid-Induced Constipation Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 21. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2021)
    Table 23. Opioid-Induced Constipation Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Opioid-Induced Constipation Product Offered
    Table 25. Date of Manufacturers Enter into Opioid-Induced Constipation Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 28. Global Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 29. Global Opioid-Induced Constipation Sales Share by Type (2017-2022)
    Table 30. Global Opioid-Induced Constipation Sales Share by Type (2023-2028)
    Table 31. Global Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Opioid-Induced Constipation Revenue Share by Type (2017-2022)
    Table 34. Global Opioid-Induced Constipation Revenue Share by Type (2023-2028)
    Table 35. Opioid-Induced Constipation Price by Type (2017-2022) & (USD/Unit)
    Table 36. Global Opioid-Induced Constipation Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 37. Global Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 38. Global Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 39. Global Opioid-Induced Constipation Sales Share by Application (2017-2022)
    Table 40. Global Opioid-Induced Constipation Sales Share by Application (2023-2028)
    Table 41. Global Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Opioid-Induced Constipation Revenue Share by Application (2017-2022)
    Table 44. Global Opioid-Induced Constipation Revenue Share by Application (2023-2028)
    Table 45. Opioid-Induced Constipation Price by Application (2017-2022) & (USD/Unit)
    Table 46. Global Opioid-Induced Constipation Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 47. North America Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 48. North America Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 49. North America Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 52. North America Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 53. North America Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 56. North America Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
    Table 57. North America Opioid-Induced Constipation Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Opioid-Induced Constipation Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 60. Europe Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 61. Europe Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 64. Europe Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 65. Europe Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 68. Europe Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
    Table 69. Europe Opioid-Induced Constipation Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Opioid-Induced Constipation Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 72. Asia Pacific Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 73. Asia Pacific Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 76. Asia Pacific Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 77. Asia Pacific Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
    Table 80. Asia Pacific Opioid-Induced Constipation Sales by Region (2023-2028) & (K Units)
    Table 81. Asia Pacific Opioid-Induced Constipation Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Opioid-Induced Constipation Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 84. Latin America Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 85. Latin America Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 88. Latin America Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 89. Latin America Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 92. Latin America Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
    Table 93. Latin America Opioid-Induced Constipation Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Opioid-Induced Constipation Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 96. Middle East and Africa Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
    Table 97. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Opioid-Induced Constipation Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 100. Middle East and Africa Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
    Table 101. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Opioid-Induced Constipation Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 104. Middle East and Africa Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
    Table 105. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Takeda Pharmaceuticals Corporation Information
    Table 108. Takeda Pharmaceuticals Description and Major Businesses
    Table 109. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 110. Takeda Pharmaceuticals Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Takeda Pharmaceuticals Recent Developments
    Table 112. Bayer Corporation Information
    Table 113. Bayer Description and Major Businesses
    Table 114. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 115. Bayer Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Bayer Recent Developments
    Table 117. Sanofi Corporation Information
    Table 118. Sanofi Description and Major Businesses
    Table 119. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 120. Sanofi Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Sanofi Recent Developments
    Table 122. Mallinckrodt Corporation Information
    Table 123. Mallinckrodt Description and Major Businesses
    Table 124. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 125. Mallinckrodt Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Mallinckrodt Recent Developments
    Table 127. Salix (Bausch Health) Corporation Information
    Table 128. Salix (Bausch Health) Description and Major Businesses
    Table 129. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 130. Salix (Bausch Health) Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Salix (Bausch Health) Recent Developments
    Table 132. AstraZeneca Corporation Information
    Table 133. AstraZeneca Description and Major Businesses
    Table 134. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 135. AstraZeneca Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. AstraZeneca Recent Developments
    Table 137. Progenics Pharmaceuticals Corporation Information
    Table 138. Progenics Pharmaceuticals Description and Major Businesses
    Table 139. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 140. Progenics Pharmaceuticals Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. Progenics Pharmaceuticals Recent Developments
    Table 142. Purdue Pharm Corporation Information
    Table 143. Purdue Pharm Description and Major Businesses
    Table 144. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 145. Purdue Pharm Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Purdue Pharm Recent Developments
    Table 147. Nektar Therapeutics Corporation Information
    Table 148. Nektar Therapeutics Description and Major Businesses
    Table 149. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 150. Nektar Therapeutics Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. Nektar Therapeutics Recent Developments
    Table 152. Daiichi Sankyo Corporation Information
    Table 153. Daiichi Sankyo Description and Major Businesses
    Table 154. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 155. Daiichi Sankyo Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Daiichi Sankyo Recent Developments
    Table 157. Prestige Corporation Information
    Table 158. Prestige Description and Major Businesses
    Table 159. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 160. Prestige Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. Prestige Recent Developments
    Table 162. GSK Corporation Information
    Table 163. GSK Description and Major Businesses
    Table 164. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 165. GSK Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 166. GSK Recent Developments
    Table 167. Shionogi Corporation Information
    Table 168. Shionogi Description and Major Businesses
    Table 169. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 170. Shionogi Opioid-Induced Constipation Product Model Numbers, Pictures, Descriptions and Specifications
    Table 171. Shionogi Recent Developments
    Table 172. Key Raw Materials Lists
    Table 173. Raw Materials Key Suppliers Lists
    Table 174. Opioid-Induced Constipation Distributors List
    Table 175. Opioid-Induced Constipation Customers List
    Table 176. Opioid-Induced Constipation Market Trends
    Table 177. Opioid-Induced Constipation Market Drivers
    Table 178. Opioid-Induced Constipation Market Challenges
    Table 179. Opioid-Induced Constipation Market Restraints
    Table 180. Research Programs/Design for This Report
    Table 181. Key Data Information from Secondary Sources
    Table 182. Key Data Information from Primary Sources
List of Figures
    Figure 1. Opioid-Induced Constipation Product Picture
    Figure 3. Global Opioid-Induced Constipation Market Share by Type in 2021 & 2028
    Figure 3. Methylnaltrexone Bromide Product Picture
    Figure 4. Lubiprostone Product Picture
    Figure 5. Naloxegol Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Opioid-Induced Constipation Market Share by Application in 2021 & 2028
    Figure 8. Hospital
    Figure 9. Pharmacy
    Figure 10. Other
    Figure 11. Opioid-Induced Constipation Report Years Considered
    Figure 12. Global Opioid-Induced Constipation Sales 2017-2028 (K Units)
    Figure 13. Global Opioid-Induced Constipation Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Opioid-Induced Constipation Revenue 2017-2028 (US$ Million)
    Figure 15. Global Opioid-Induced Constipation Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 16. Global Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
    Figure 17. Global Opioid-Induced Constipation Sales Market Share by Region (2023-2028)
    Figure 18. North America Opioid-Induced Constipation Sales YoY (2017-2028) & (K Units)
    Figure 19. North America Opioid-Induced Constipation Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Europe Opioid-Induced Constipation Sales YoY (2017-2028) & (K Units)
    Figure 21. Europe Opioid-Induced Constipation Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Asia-Pacific Opioid-Induced Constipation Sales YoY (2017-2028) & (K Units)
    Figure 23. Asia-Pacific Opioid-Induced Constipation Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Latin America Opioid-Induced Constipation Sales YoY (2017-2028) & (K Units)
    Figure 25. Latin America Opioid-Induced Constipation Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Middle East & Africa Opioid-Induced Constipation Sales YoY (2017-2028) & (K Units)
    Figure 27. Middle East & Africa Opioid-Induced Constipation Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. The Opioid-Induced Constipation Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 29. The Top 5 and 10 Largest Manufacturers of Opioid-Induced Constipation in the World: Market Share by Opioid-Induced Constipation Revenue in 2021
    Figure 30. Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 31. Global Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 32. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 33. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 34. Global Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 35. North America Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 36. North America Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 37. North America Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 38. North America Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 39. North America Opioid-Induced Constipation Sales Share by Country (2017-2028)
    Figure 40. North America Opioid-Induced Constipation Revenue Share by Country (2017-2028)
    Figure 41. U.S. Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 42. Canada Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 43. Europe Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 44. Europe Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 45. Europe Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 46. Europe Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 47. Europe Opioid-Induced Constipation Sales Share by Country (2017-2028)
    Figure 48. Europe Opioid-Induced Constipation Revenue Share by Country (2017-2028)
    Figure 49. Germany Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 50. France Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 51. U.K. Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 52. Italy Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 53. Russia Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 54. Asia Pacific Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 57. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Opioid-Induced Constipation Sales Share by Region (2017-2028)
    Figure 59. Asia Pacific Opioid-Induced Constipation Revenue Share by Region (2017-2028)
    Figure 60. China Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 61. Japan Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 62. South Korea Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 63. India Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 64. Australia Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 65. Taiwan Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 66. Indonesia Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 67. Thailand Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 68. Malaysia Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 69. Philippines Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 70. Latin America Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 71. Latin America Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 72. Latin America Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 73. Latin America Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 74. Latin America Opioid-Induced Constipation Sales Share by Country (2017-2028)
    Figure 75. Latin America Opioid-Induced Constipation Revenue Share by Country (2017-2028)
    Figure 76. Mexico Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 77. Brazil Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 78. Argentina Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 79. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
    Figure 82. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Opioid-Induced Constipation Sales Share by Country (2017-2028)
    Figure 84. Middle East and Africa Opioid-Induced Constipation Revenue Share by Country (2017-2028)
    Figure 85. Turkey Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 86. Saudi Arabia Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 87. U.A.E Opioid-Induced Constipation Revenue (2017-2028) & (US$ Million)
    Figure 88. Opioid-Induced Constipation Value Chain
    Figure 89. Opioid-Induced Constipation Production Process
    Figure 90. Channels of Distribution
    Figure 91. Distributors Profiles
    Figure 92. Bottom-up and Top-down Approaches for This Report
    Figure 93. Data Triangulation
    Figure 94. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Frequently Asked Questions
Opioid-Induced Constipation report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Opioid-Induced Constipation report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Opioid-Induced Constipation report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Optical Encoders

Optical Encoders market is segmented by Type and by Application. Players, stakeholders, and other ... Read More

Optical Films

Optical Films market is segmented by Type and by Application. Players, stakeholders, and other pa ... Read More

Organic Apple Juice

Organic Apple Juice market is segmented by Type and by Application. Players, stakeholders, and ot ... Read More